Literature DB >> 20927007

Five-step clinical assessment in spastic paresis.

Jean-Michel Gracies1, N Bayle, M Vinti, S Alkandari, P Vu, C M Loche, C Colas.   

Abstract

Among the three main factors of motor impairment that emerge in chronological order following a lesion to central motor pathways, the last two antagonize movement: 1) stretch-sensitive paresis, a reduction of agonist motor unit recruitment upon voluntary command, worsened by antagonist stretch; 2) soft tissue contracture, and 3) muscle overactivity. Types of muscle overactivity include 1) spasticity, an increase in the velocity-dependent response to muscle stretch, measured at rest; 2) spastic dystonia, i.e., chronic tonic muscle activity at rest, sensitive to stretch of the dystonic muscle and 3) spastic co-contraction, an inappropriate degree of antagonistic contraction during voluntary agonist command, sensitive to stretch of the co-contracting muscle. A five-step clinical assessment may closely parallel this phenomenology, in which the first four steps aim at quantifying the antagonistic potential of each muscle group. Step-1 measures passive range of motion, i.e., the angle of arrest upon slow stretch of the muscle group assessed (minimizing spastic dystonia), which provides insight on soft tissue length and extensibility. Step-2 measures the angle of catch or clonus upon fast passive stretch of the muscle group assessed, which provides insight on stretch reflex excitability. Step-3 measures the range of active motion against the muscle group assessed, a net result of agonist recruitment minus the combined resistance from passive soft tissue stiffness and spastic co-contraction in the muscle group assessed. Step-4 measures the maximal frequency of rapid alternating movements along the maximal active range of motion, evaluating Step-3 performance repeatability. Step-5 evaluates active function, using for example a walking test (10 m or 2 min) for lower limb and the Modified Frenchay Scale for upper limb assessment, and perceived function through patient global subjective assessment.

Entities:  

Mesh:

Year:  2010        PMID: 20927007

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  14 in total

1.  Management of intrathecal baclofen therapy for severe acquired brain injury: consensus and recommendations for good clinical practice.

Authors:  Antonio De Tanti; Federico Scarponi; Michele Bertoni; Giulio Gasperini; Bernardo Lanzillo; Franco Molteni; Federico Posteraro; Dino Francesco Vitale; Mauro Zanpolini
Journal:  Neurol Sci       Date:  2017-05-06       Impact factor: 3.307

2.  Guided Self-rehabilitation Contracts Combined With AbobotulinumtoxinA in Adults With Spastic Paresis.

Authors:  Jean-Michel Gracies; Gerard E Francisco; Robert Jech; Svetlana Khatkova; Carl D Rios; Pascal Maisonobe
Journal:  J Neurol Phys Ther       Date:  2021-07-01       Impact factor: 3.649

3.  Comprehensive neuromechanical assessment in stroke patients: reliability and responsiveness of a protocol to measure neural and non-neural wrist properties.

Authors:  Hanneke van der Krogt; Asbjørn Klomp; Jurriaan H de Groot; Erwin de Vlugt; Frans Ct van der Helm; Carel Gm Meskers; J Hans Arendzen
Journal:  J Neuroeng Rehabil       Date:  2015-03-13       Impact factor: 4.262

4.  Effects of repeated abobotulinumtoxinA injections in upper limb spasticity.

Authors:  Jean-Michel Gracies; Michael O'Dell; Michele Vecchio; Peter Hedera; Serdar Kocer; Monika Rudzinska-Bar; Bruce Rubin; Sofiya L Timerbaeva; Anna Lusakowska; François Constant Boyer; Anne-Sophie Grandoulier; Claire Vilain; Philippe Picaut
Journal:  Muscle Nerve       Date:  2017-08-13       Impact factor: 3.217

5.  Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.

Authors:  Jean-Michel Gracies; Alberto Esquenazi; Allison Brashear; Marta Banach; Serdar Kocer; Robert Jech; Svetlana Khatkova; Ján Benetin; Michele Vecchio; Peter McAllister; Jan Ilkowski; Stanislaw Ochudlo; France Catus; Anne Sophie Grandoulier; Claire Vilain; Philippe Picaut
Journal:  Neurology       Date:  2017-11-01       Impact factor: 9.910

6.  Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity.

Authors:  Sameh Ghroubi; Samar Alila; Wafa Elleuch; Houda Ben Ayed; Chokri Mhiri; Mohamed Habib Elleuch
Journal:  Pan Afr Med J       Date:  2020-02-25

7.  Comprehensive evaluation of gait, spasticity, and muscle morphology: A case report of a child with spastic paresis treated with Botulinum NeuroToxin-A, serial casting, and physiotherapy.

Authors:  Guido Weide; Lizeth Sloot; Laura Oudenhoven; Richard T Jaspers; Jaap Harlaar; Annemieke Buizer; Lynn Bar-On
Journal:  Clin Case Rep       Date:  2019-07-21

8.  Muscle Shortening and Spastic Cocontraction in Gastrocnemius Medialis and Peroneus Longus in Very Young Hemiparetic Children.

Authors:  M Vinti; N Bayle; A Merlo; G Authier; S Pesenti; J-L Jouve; B Chabrol; J-M Gracies; C Boulay
Journal:  Biomed Res Int       Date:  2018-05-21       Impact factor: 3.411

9.  Motor Overflow and Spasticity in Chronic Stroke Share a Common Pathophysiological Process: Analysis of Within-Limb and Between-Limb EMG-EMG Coherence.

Authors:  Yen-Ting Chen; Shengai Li; Elaine Magat; Ping Zhou; Sheng Li
Journal:  Front Neurol       Date:  2018-10-09       Impact factor: 4.003

10.  The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia.

Authors:  Yen-Ting Chen; Chuan Zhang; Yang Liu; Elaine Magat; Monica Verduzco-Gutierrez; Gerard E Francisco; Ping Zhou; Yingchun Zhang; Sheng Li
Journal:  Toxins (Basel)       Date:  2020-07-31       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.